116 related articles for article (PubMed ID: 17918788)
1. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis.
Mittendorf T; Dietz B; Sterz R; Kupper H; Cifaldi MA; von der Schulenburg JM
J Rheumatol; 2007 Dec; 34(12):2343-50. PubMed ID: 17918788
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
[TBL] [Abstract][Full Text] [Related]
3. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.
Torrance GW; Tugwell P; Amorosi S; Chartash E; Sengupta N
Rheumatology (Oxford); 2004 Jun; 43(6):712-8. PubMed ID: 15039494
[TBL] [Abstract][Full Text] [Related]
4. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
Kimel M; Cifaldi M; Chen N; Revicki D
J Rheumatol; 2008 Feb; 35(2):206-15. PubMed ID: 18085743
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
7. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
[TBL] [Abstract][Full Text] [Related]
9. Concurrent psychiatric disorders are associated with significantly poorer quality of life in patients with rheumatoid arthritis.
Mok CC; Lok EY; Cheung EF
Scand J Rheumatol; 2012 Aug; 41(4):253-9. PubMed ID: 22657161
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.
Yount S; Sorensen MV; Cella D; Sengupta N; Grober J; Chartash EK
Clin Exp Rheumatol; 2007; 25(6):838-46. PubMed ID: 18173917
[TBL] [Abstract][Full Text] [Related]
12. Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab.
Herenius MM; Hoving JL; Sluiter JK; Raterman HG; Lems WF; Dijkmans BA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
J Occup Environ Med; 2010 Jun; 52(6):618-21. PubMed ID: 20523240
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
14. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
15. Work ability: a new outcome measure in rheumatoid arthritis?
Raterman HG; Hoving JL; Nurmohamed MT; Herenius MM; Sluiter JK; Lems WF; Tak PP; Dijkmans BA; Twisk J; Frings-Dresen MH; Voskuyl AE
Scand J Rheumatol; 2010 Mar; 39(2):127-31. PubMed ID: 20059369
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis.
Rudwaleit M; Gooch K; Michel B; Herold M; Thörner A; Wong R; Kron M; Chen N; Kupper H
J Rheumatol; 2011 Jan; 38(1):79-86. PubMed ID: 20952469
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS
J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505
[TBL] [Abstract][Full Text] [Related]
18. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
[TBL] [Abstract][Full Text] [Related]
19. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis.
Wells G; Li T; Maxwell L; Maclean R; Tugwell P
Ann Rheum Dis; 2008 Feb; 67(2):260-5. PubMed ID: 17846044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
